Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion

• Main Authors: Udaondo P, Garcia-Delpech S, Salom D, Garcia-Pous M, Diaz-Llopis M.
• Format: Article
• Language: English
• Published: Dove Medical Press 2011-07-01
• Series: Clinical Ophthalmology
• Online Access: http://www.dovepress.com/intravitreal-pegaptanib-for-refractory-macular-edema-secondary-to-reti-a7821

Patricia Udaondo1,2, Salvador Garcia-Delpech1,3, David Salom1,3, Maria Garcia-Pous1,3, Manuel Diaz-Llopis1,31Nuevo Hospital Universitario y Politecnico La Fe, Valencia, Spain; 2University Cardenal Herrera CEU, Valencia, Spain; 3Faculty of Medicine, University of Valencia, Valencia, SpainPurpose: To assess the efficacy of intravitreal Pegaptanib sodium (Macugen®) injection in the management of refractory macular edema secondary to branch retinal vein occlusion.Methods: This is a prospective, nonrandomized, interventional case series. Five eyes of five patients with macular edema refractory to either bevacizumab or triamcinolone were treated with intravitreal injection of Pegaptanib sodium.Results: After three months follow-up, both visual acuity and macular edema, measured by optical coherence tomography and fluorescence angiography, dramatically improved.Conclusion: Pegaptanib sodium is a safe and efficacy treatment for macular edema secondary to branch retinal vein occlusion.Keywords: Macugen®, BRVO, BCVA, pegaptanib sodium